`
`Page 1
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF NEW JERSEY
`
`JANSSEN R&D IRELAND,
`
`et al.,
`
`Plaintiffs,
`
`VS.
`
`LUPIN LIMITED, et al. ,
`
`Defendants.
`
`\/\/\/\/\/\/\/\/\/é
`
`Civil Action No.
`
`10-5954 (WHW)
`
`(MCA)
`
`HIGHLY CONFIDENTIAL
`
`The videotaped deposition of MICHAEL JOHN
`
`ZAWOROTKO, Ph.D., called for examination,
`
`taken
`
`pursuant to the Federal Rules of Civil Procedure
`
`of the United States District Courts pertaining to
`
`the taking of depositions,
`
`taken before JANET L.
`
`ROBBINS, CSR No. 84-2207, Certified Shorthand
`
`Reporter of the State of Illinois, at 6 West
`
`Hubbard Street, Suite 500, Chicago, Illinois, on
`
`October 11, 2013, at 9:03 a.m.
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`212-267-6868
`
`wnVwnVerfieXLcon1
`
`516-608-2400
`
`VERHEXTREPOKHNGCONWANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR201501030
`
`(Page1 of8)
`
`
`
`HIGHLY CONFIDENTIAL
`
`Q.
`
`A.
`
`In general any API.
`
`There are many, many, many, many
`
`instances of hydrates and solvates forming from
`
`impurities in the solution, many, many examples.
`
`Q.
`
`Can you point me to a single example
`
`showing that an ethanolate was formed based on the
`
`presence of an ethanol stabilizer in methylene
`
`chloride solution?
`
`10
`
`11
`
`12
`
`13
`
`14
`
`A.
`
`No, but there are many, many, many
`
`examples of organic molecules forming solvates or
`
`hydrates from very low concentrations of the
`
`solvent or —— or water in the solution.
`
`Q.
`
`Have you ever formed an ethanolate of
`
`any API using methylene chloride to synthesis the
`
`API?
`
`Page 193
`
`03:01:30
`
`03:01:
`
`33
`
`03:01:
`
`35
`
`03:01:
`
`41
`
`03:01:
`
`45
`
`03:01:
`
`48
`
`03:01:
`
`51
`
`03:01:
`
`56
`
`03:01:
`
`58
`
`03:02:
`
`02
`
`03:02:
`
`06
`
`03:02:
`
`12
`
`03:02:
`
`15
`
`03:02:
`
`19
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`A.
`
`I have used methylene chloride in
`
`ethanol as a mixed solvent before consciously, but
`
`I don't recall what the outcome of those
`
`experiments was.
`
`Q.
`
`My question is: Have you ever formed
`
`an ethanolate of any API using methylene chloride
`
`in the synthesis of that API?
`
`A.
`
`Q.
`
`No, not to my knowledge.
`
`Ghosh 1998 does not teach how to make
`
`an ethanolate form of darunavir, correct?
`
`03:02:
`
`26
`
`03:02:
`
`29
`
`03:02:
`
`31
`
`03:02:
`
`36
`
`03:02:
`
`39
`
`03:02:
`
`39
`
`03:02:
`
`42
`
`03:02:
`
`51
`
`03:02:
`
`55
`
`03:03:
`
`06
`
`03:03:
`
`12
`
`212-267-6868
`
`wWw.Veritext.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 2 of 8)
`
`
`
`HIGHLY CONFIDENTIAL
`
`MS. RAGHAVAN: Objection to form, vague
`
`as to the term "teach."
`
`THE WITNESS:
`
`If teach —— if by teach
`
`you mean provides enough information for a
`
`person of ordinary skill in the art to get to
`
`darunavir —— crystalline darunavir
`
`monoethanolate,
`
`I believe that the Ghosh 1998
`
`does, as I detail in my report.
`
`BY MS. ROYZMAN:
`
`Q.
`
`The question is: Does Ghosh 1998
`
`provide any conditions for crystallizing
`
`darunavir?
`
`vague.
`
`MS. RAGHAVAN: Objection to the form,
`
`10
`
`11
`
`12
`
`13
`
`14
`
`Page 194
`
`03:03:17
`
`03:
`
`03:
`
`22
`
`03:
`
`03:
`
`30
`
`03:
`
`03:
`
`46
`
`03:
`
`03:
`
`50
`
`03:
`
`03:
`
`55
`
`03:
`
`03:
`
`57
`
`03:
`
`04:
`
`01
`
`03:
`
`04:
`
`04
`
`03:
`
`04:
`
`04
`
`03:
`
`04:
`
`08
`
`03:
`
`04:
`
`13
`
`03:
`
`04:
`
`13
`
`03:
`
`04:
`
`15
`
`04:
`
`22
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`THE WITNESS:
`
`It does not provide any
`
`specific conditions. But as I detail in my
`
`report,
`
`I believe that it —— nevertheless,
`
`that the —— or,
`
`I should say,
`
`that the
`
`03:
`
`03:
`
`04:
`
`28
`
`03:
`
`04:
`
`30
`
`03:
`
`04:
`
`39
`
`isolation of the solid form is obvious to a
`
`03:
`
`04:
`
`41
`
`person of skill in the art,
`
`the step of
`
`isolation would be obvious to a person of
`
`skill in the art.
`
`MS. ROYZMAN: Let's go off the record
`
`and take a break.
`
`MS. RAGHAVAN: Okay.
`
`03:
`
`04:
`
`44
`
`03:
`
`04:
`
`47
`
`03:
`
`04:
`
`51
`
`03:
`
`04:
`
`54
`
`03:
`
`04:
`
`55
`
`03:
`
`04:
`
`56
`
`212-267-6868
`
`wWw.VeriteXt.c0m
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 3 of 8)
`
`
`
`HIGHLY CONFIDENTIAL
`
`Page 195
`
`THE VIDEOGRAPHER: This is the end of
`
`03:04:57
`
`Media No. 3. We're going off the record.
`
`The time is 3:03 p.m.
`
`(A recess was had.)
`
`03:05:
`
`02
`
`03:05:
`
`04
`
`03:24:
`
`22
`
`THE VIDEOGRAPHER: This is the
`
`03:24:
`
`22
`
`beginning of Media No. 4. We are back on the
`
`record.
`
`The time is 3:23 p.m.
`
`Please proceed.
`
`(Zaworotko Exhibit 13 was marked
`
`for identification.)
`
`BY MS. ROYZMAN:
`
`Q.
`
`Dr. Zaworotko, let me hand you as
`
`Exhibit No. 13 U.S. Patent 6,248,775,
`
`issued
`
`June 19, 2001.
`
`10
`
`11
`
`12
`
`13
`
`14
`
`03:24:
`
`37
`
`03:24:
`
`40
`
`03:24:
`
`43
`
`09:27:
`
`54
`
`03:24:
`
`43
`
`03:24:
`
`43
`
`03:24:
`
`44
`
`03:24:
`
`46
`
`03:24:
`
`56
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`I believe you refer to this patent as
`
`the '775 patent in your expert report and that we
`
`have been talking about from time to time today.
`
`MS. RAGHAVAN: This is 13?
`
`THE WITNESS: Yeah, my lucky number.
`
`MS. RAGHAVAN: Okay.
`
`03:24:
`
`57
`
`03:24:
`
`59
`
`03:25:
`
`04
`
`03:25:
`
`08
`
`03:25:
`
`12
`
`03:25:
`
`15
`
`MR. REDDY:
`
`I think Ghosh '98 was
`
`03:25:
`
`22
`
`Exhibit 13, wasn't it?
`
`THE WITNESS: No, it was 14 --
`
`MR. REDDY: Oh.
`
`03:25:
`
`24
`
`03:25:
`
`26
`
`THE WITNESS:
`
`—— according to this.
`
`03:25:
`
`27
`
`212-267-6868
`
`wWw.Veritext.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 4 of 8)
`
`
`
`HIGHLY CONFIDENTIAL
`
`Q.
`
`Okay.
`
`So darunavir was patented as of
`
`June 19, 2001, correct?
`
`MR. REDDY: Objection to the extent it
`
`seeks a legal conclusion and outside the
`
`scope of his report.
`
`Page 197
`
`03:26:36
`
`03:
`
`26:
`
`42
`
`03:
`
`26:
`
`49
`
`03:
`
`26:
`
`52
`
`03:
`
`26:
`
`54
`
`THE WITNESS:
`
`The —— the date of the
`
`03:
`
`26:
`
`59
`
`issue of the patent was June 2001.
`
`I'm --
`
`I'm just curious about the priority date,
`
`which is why I was looking in there, but
`
`it's --
`
`BY MS. ROYZMAN:
`
`Q.
`
`I can tell you what the priority date
`
`is.
`
`The priority date is August 1994 --
`
`So it's ahead --
`
`10
`
`11
`
`12
`
`13
`
`03:
`
`27:
`
`09
`
`03:
`
`27:
`
`13
`
`03:
`
`27:
`
`16
`
`03:
`
`27:
`
`18
`
`03:
`
`27:
`
`18
`
`03:
`
`27:
`
`18
`
`03:
`
`27:
`
`20
`
`03:
`
`27:
`
`25
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`Yeah.
`
`—— for —— for darunavir.
`
`Yeah, it's ahead of Ghosh '98.
`
`Yes. And so darunavir was patented
`
`prior to the filing of your
`
`'613 patent which
`
`lists a variety of anti—HIV compounds, correct?
`
`MS. RAGHAVAN: Objection to the form.
`
`THE WITNESS:
`
`I'll have to go back.
`
`MS. RAGHAVAN:
`
`I think you're referring
`
`to Zaworotko Exhibit 11, right?
`
`MS. ROYZMAN:
`
`I believe so, yes.
`
`MS. RAGHAVAN: Yeah.
`
`03:
`
`27:
`
`27
`
`03:
`
`27:
`
`29
`
`03:
`
`27:
`
`40
`
`03:
`
`27:
`
`46
`
`03:
`
`27:
`
`53
`
`03:
`
`28:
`
`00
`
`03:
`
`28:
`
`01
`
`03:
`
`28:
`
`05
`
`03:
`
`28:
`
`08
`
`212-267-6868
`
`wWw.VeriteXt.c0m
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 5 of 8)
`
`
`
`HIGHLY CONFIDENTIAL
`
`THE WITNESS: Yes.
`
`BY MS. ROYZMAN:
`
`Q.
`
`Okay. And does claim 7 provide any
`
`crystallization conditions for darunavir?
`
`MS. RAGHAVAN: Objection to the form,
`
`vague.
`
`THE WITNESS: Claim 7 provides a
`
`Page 198
`
`03:28:08
`
`03:
`
`28:
`
`09
`
`03:
`
`28:
`
`09
`
`03:
`
`28:
`
`23
`
`03:
`
`28:
`
`27
`
`03:
`
`28:
`
`28
`
`03:
`
`28:
`
`30
`
`structural formula for darunavir.
`
`In order
`
`03:
`
`28:
`
`35
`
`for that claim to be issued,
`
`I would assume
`
`that there is detail concerning how to
`
`isolate darunavir in the specification.
`
`BY MS. ROYZMAN:
`
`Q.
`
`Okay. Does claim 7 provide of a
`
`structure for darunavir monoethanolate?
`
`10
`
`11
`
`12
`
`13
`
`14
`
`03:
`
`28:
`
`40
`
`03:
`
`28:
`
`43
`
`03:
`
`28:
`
`47
`
`03:
`
`28:
`
`51
`
`03:
`
`28:
`
`51
`
`03:
`
`28:
`
`57
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`MS. RAGHAVAN: Objection to the form,
`
`vague.
`
`THE WITNESS:
`
`To go back to where we
`
`were very early today,
`
`there's a difference
`
`03:
`
`29:
`
`02
`
`03:
`
`29:
`
`04
`
`03:
`
`29:
`
`04
`
`03:
`
`29:
`
`15
`
`between a molecule and a material. And claim
`
`03:
`
`29:
`
`20
`
`3 simply provides the structure of the
`
`molecule whereas darunavir —— crystalline
`
`03:
`
`29:
`
`24
`
`03:
`
`29:
`
`27
`
`darunavir monoethanolate is a material.
`
`So
`
`03:
`
`29:
`
`33
`
`they are —— they don't mean the same thing
`
`with respect to molecules, materials and
`
`medicines.
`
`03:
`
`29:
`
`36
`
`03:
`
`29:
`
`43
`
`03:
`
`29:
`
`49
`
`212-267-6868
`
`wWw.VeriteXt.c0m
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 6 of 8)
`
`
`
`HIGHLY CONFIDENTIAL
`
`BY MS. ROYZMAN:
`
`Q.
`
`Dr. Zaworotko,
`
`just so the record is
`
`clear,
`
`I believe you misspoke. Claim 7 is the
`
`claim to the darunavir molecule, correct?
`
`MS. RAGHAVAN: Objection to the form,
`
`calls for a legal conclusion.
`
`BY MS. ROYZMAN:
`
`Q.
`
`A.
`
`I think you said claim 3.
`
`Oh, sorry.
`
`I'm looking —— yeah, a
`
`10
`
`11
`
`12
`
`13
`
`14
`
`compound —— never mind.
`
`Sorry.
`
`Yeah, claim 7 provides the structural
`
`formula of a compound, which we now know is
`
`darunavir, but it refers to the molecule and not
`
`the material.
`
`Page 199
`
`03:29:49
`
`03:29:
`
`50
`
`03:29:
`
`51
`
`03:29:
`
`54
`
`03:29:
`
`58
`
`03:30:
`
`02
`
`03:30:
`
`05
`
`03:30:
`
`06
`
`03:30:
`
`07
`
`03:30:
`
`10
`
`03:30:
`
`11
`
`03:30:
`
`14
`
`03:30:
`
`20
`
`03:30:
`
`24
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Q.
`
`Okay.
`
`So you don't see in claim 7 any
`
`reference to darunavir monoethanolate, correct?
`
`MS. RAGHAVAN: Objection to the form,
`
`calls for a legal conclusion.
`
`03:30:
`
`25
`
`03:30:
`
`29
`
`03:30:
`
`33
`
`03:30:
`
`36
`
`THE WITNESS:
`
`I would not want to
`
`03:30:
`
`38
`
`ask —— answer that question without being
`
`able to review the document in its entirety
`
`03:30:
`
`45
`
`03:30:
`
`46
`
`so that I could determine what information is
`
`03:30:
`
`50
`
`provided in the specification about the
`
`nature of what that means.
`
`So I would not interpret that that
`
`03:30:
`
`54
`
`03:30:
`
`57
`
`03:31:
`
`00
`
`212-267-6868
`
`wWw.Veritext.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 7 of 8)
`
`
`
`HIGHLY CONFIDENTIAL
`
`means it's just the molecule unless I had
`
`Page 200
`
`03:31:03
`
`read how the molecule was characterized and
`
`03:31:
`
`07
`
`whether it was characterized as a material or
`
`03:31:
`
`10
`
`as a molecule or both.
`
`BY MS. ROYZMAN:
`
`Q.
`
`Okay.
`
`Just looking at claim 7, do you
`
`see darunavir monoethanolate there?
`
`MS. RAGHAVAN: Objection to the form,
`
`vague.
`
`THE WITNESS: You're asking me a
`
`question out of the context of the document
`
`03:31:
`
`14
`
`03:31:
`
`17
`
`03:31:
`
`18
`
`03:31:
`
`22
`
`03:31:
`
`26
`
`03:31:
`
`28
`
`03:31:
`
`28
`
`03:31:
`
`29
`
`as a whole. And what I know about claims is
`
`03:31:
`
`32
`
`that they have to be interpreted in the
`
`context of the specification.
`
`03:31:
`
`35
`
`03:31:
`
`37
`
`03:31:
`
`40
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`So it could mean, it could be that if I
`
`were to go through the document, I'd find the
`
`crystal structure of darunavir monoethanolate
`
`and that's what led to that claim.
`
`So you're asking me to know what's in
`
`the specification in order to interpret what
`
`that means.
`
`BY MS. ROYZMAN:
`
`Q.
`
`Okay.
`
`I'm really trying to ask a very
`
`simple question.
`
`It's just with your eyes looking
`
`at column 221, claim 7, do you see darunavir
`
`03:31:
`
`45
`
`03:31:
`
`47
`
`03:31:
`
`51
`
`03:31:
`
`53
`
`03:31:
`
`55
`
`03:31:
`
`58
`
`03:31:
`
`59
`
`03:31:
`
`59
`
`03:32:
`
`01
`
`03:32:
`
`04
`
`212-267-6868
`
`wWw.Veritext.com
`
`516-608-2400
`
`VERITEXT REPORTING COMPANY
`
`Janssen Ex. 2028
`
`Lupin Ltd. v. Janssen Sciences Ireland UC
`|PR2015-01030
`
`(Page 8 of 8)